Kite, a Gilead Company, and Arcellx have revealed significant developments in their collaborative anitocabtagene autoleucel (anito-cel) multiple myeloma program. This program marks the first investigation of BCMA CAR T in multiple myeloma, utilizing Arcellx’s innovative and compact D-Domain binder. This article summarizes the key operational updates, including the design of a global Phase 3 randomized controlled clinical trial called iMMagine-3.
Operational Updates and Trial Design:Kite and Arcellx have provided operational updates on their anito-cel multiple myeloma program. The partners detailed the design of a global Phase 3, randomized controlled clinical trial named iMMagine-3. This trial aims to further advance the investigation of anito-cel in multiple myeloma treatment. By utilizing Arcellx’s novel D-Domain binder, which offers a compact design, the companies have achieved a breakthrough in treating this type of cancer.
ASCO Annual Meeting s:Gilead Sciences, Inc. the parent company of Kite, alongside Kite itself, will present 18 abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These abstracts highlight the commitment of Gilead and Kite to developing diverse and innovative approaches to transform cancer treatment. The data encompasses various solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia, and lymphoma.
FDA Approval for Biktarvy Label Update:Gilead Sciences, Inc. has recently received approval from the U.S. Food and Drug Administration (FDA) for an updated label for Biktarvy. This label update includes additional data, further reinforcing the drug’s safety and efficacy profile in treating pregnant individuals with HIV-1 who have suppressed viral loads. The additional data are derived from Study 5310, which extensively evaluated the pharmacokinetics, safety, and efficacy of Biktarvy.
Comments